Swiss regulator approves Roche-Regeneron Covid-19 drug
The Swiss medicines agency, Swissmedic, has given the green light to the monoclonal antibody cocktail Ronapreve developed by Roche and Regeneron for use in the treatment and prevention of Covid-19.
Ronapreve, a combination of two monoclonal antibodies (casirivimab and imdevimab), is approved for patients 12 years and up when “oxygen therapy or hospitalisation is not required and there is a high risk of developing a severe form of Covid-19,” Swissmedic said in a statementExternal link.
Monoclonal antibodies are laboratory-made proteins that mimic the immune system’s ability to fight off harmful pathogens such as viruses.
The treatment can also be taken prophylactically when the immune response to Covid-19 vaccination is not adequate. It is the first drug authorised by the Swiss regulator for the prevention of Covid-19 in cases where there is not a sufficient immune response after vaccination due to other diseases or treatments.
Ronapreve is given as a single infusion into a vein or by injection under the skin. The application for the authorisation of the drug, submitted on March 5, didn’t include data on the efficacy of the drug against the Omicron variant.
Since-April, Ronapreve could be administered under the exceptions allowed in the Covid-19 Ordinance 3; an ordinance published by the Federal Council in June 2020 to combat the pandemic. This includes a list of products that can be placed on the market before the authorisation procedure is concluded.
The antibody cocktail has been authorised in several other locations including in Japan and the European Union. It has a conditional approval in the UK and Australia and is available for emergency use in the United States.
More orders
The Federal Office of Public Health (FOPH) has been building up its Covid-19 treatment reserves. On Monday, the FOPH announced that it had signed two additional contracts for more doses of both Ronapreve (4,000 doses) and the monoclonal drug sotrovimab (2,000 doses) developed by GlaxoSmithKline and Vir Biotechnology. The antibody for the latter was discovered by Swiss company Humabs BioMed.
This is on top of the 3,000 doses of each drug the government ordered earlier this year. Contract amounts are confidential for both drugs, according to the FOPH.
External Content
Your subscription could not be saved. Please try again.
Almost finished… We need to confirm your email address. To complete the subscription process, please click the link in the email we just sent you.
‘Alpha Uno’: Swiss fighter jets take off and land on motorway
This content was published on
The Swiss Air Force is conducting a military exercise on the motorway in canton Vaud between the Payerne and Avenches municipalities on Wednesday.
Federal offices and Xplain adopt data protection recommendations
This content was published on
Swiss authorities and its private contract processors are required to review their cooperation after an investigation into leaked data.
This content was published on
Heavy rainfall has caused severe flooding in northern Armenia and cost lives. Switzerland dispatched a team of seven engineers to the region.
Swiss House of Representatives does not want to recognise Palestine as a state
This content was published on
By 131 votes to 61 with 2 abstentions, the House of Representatives said 'no' to the postulate put forth by the Social Democratic Party.
This content was published on
The peak of the snow accumulation was most likely reached on Monday, wrote glaciologist Matthias Huss on the social media platform X on Tuesday.
US Vice President Harris to attend Ukraine peace conference
This content was published on
US Vice President Kamala Harris and US President Joe Biden's security advisor, Jake Sullivan, will take part in the Ukraine peace conference.
FINMA director expects cooperation and transparency from banks
This content was published on
"I demand complete and unfiltered access to all information", said the director of the Swiss Financial Market Supervisory Authority said in an interview.
Swiss pharma reckons with its past, present and future
This content was published on
This is the story of how making drugs helped turn a small, mountainous country into an industry titan, and what the pandemic means for its future.
This content was published on
Swiss biopharma firm Roche has been granted emergency authorisation by US authorities to sell its at-home rapid Covid-19 test starting in January.
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.